

**SUPPLEMENTAL TABLE A: Second primary malignancy depending on timing of diagnosis in 200 patients with well-differentiated thyroid cancer**


<b>Neoplasm</b>	<b>All Patients</b>	<b>Anachronous and Synchronous</b>	<b>Metachronous</b>
<b>All sites</b>	200	85 (42.5%) [71 ; 14]	115 (57.5%)
<b>Oral cavity and pharynx</b>	28 (14.0%)	22 (25.9%) [17 ; 5]	6 (5.2%)
<b>Digestive system</b>	44 (22.0%)	14 (16.5%) [14 ; 0]	30 (26.1%)
<b>Respiratory system</b>	18 (9.0%)	2 (2.4%) [0 ; 2]	16 (13.9%)
<b>Bones and joints</b>	2 (1.0%)	0	2 (1.7%)
<b>Soft tissue</b>	3 (1.5%)	1 (1.2%) [0 ; 1]	2 (1.7%)
<b>Skin</b>	6 (3.0%)	3 (3.5%) [2 ; 1]	3 (2.6%)
<b>Breast</b>	45 (22.5%)	18 (21.2%) [16 ; 2]	27 (23.5%)
<b>Female genital system</b>	19 (9.5%)	10 (11.8%) [7 ; 3]	9 (7.8%)
<b>Male genital system</b>	5 (2.5%)	3 (3.5%) [3 ; 0]	2 (1.7%)
<b>Urinary system</b>	13 (6.5%)	8 (9.4%) [8 ; 0]	5 (4.3%)
<b>Endocrine system</b>	1 (0.5%)	0	1 (0.9%)
<b>Lymphoma</b>	6 (3.0%)	2 (2.4%) [2 ; 0]	4 (3.5%)
<b>Leukemia</b>	6 (3.0%)	1 (1.2%) [1 ; 0]	5 (4.3%)
<b>Miscellaneous</b>	4 (2.0%)	1 (1.2%) [1 ; 0]	3 (2.6%)

Anachronous, diagnosed 6 months before thyroid cancer diagnosis; synchronous, and metachronous, diagnosed 6 months after thyroid cancer diagnosis

**SUPPLEMENTAL TABLE B: Clinical features of 2,864 cases of well-differentiated thyroid cancer classified into metachronous and non-metachronous groups**

<b>Clinical characteristic</b>	<b>No SPM or anachronous/synchronous SPM</b>	<b>Metachronous SPM</b>	<b><i>P</i></b>
<b>Patient number</b>	2,749 (96.0%)	115 (4.0%)	
<b>Gender (female)</b>	2172 (79.0%)	84 (73.0%)	0.1252
<b>Age at diagnosis (year)</b>	43.7 ± 14.4	50.6 ± 12.5	0.0001
<b>Mean tumor size (cm)</b>	2.4 ± 1.7	2.5 ± 1.5	0.7649
<b>Thyroid operative method</b>			0.0270
<b>Total thyroidectomy</b>	2336 (85.0%)	89 (77.4%)	
<b>Less than total thyroidectomy</b>	413 (15.0%)	26 (22.6%)	
<b>TNM stage</b>			0.0044
<b>Stage I</b>	1889 (68.7%)	61 (53.0%)	
<b>Stage II</b>	272 (9.9%)	15 (13.0%)	
<b>Stage III</b>	214 (7.8%)	15 (13.0%)	
<b>Stage IV</b>	374 (13.6%)	24 (20.9%)	
<b>Non-remission</b>	434 (15.8%)	32 (27.8%)	0.0006
<b>Follow-up period (year)</b>	9.4 ± 6.7	11.7 ± 6.6	0.0002
<b>Post-operative <sup>131</sup>I accumulative dose (mCi)</b>	127.3 ± 187.0	209.8 ± 302.0	0.0001
<sup>131</sup> I dose ≥ 30 mCi	2376 (86.4%)	101 (87.8%)	0.6682
<b>Radiation therapy</b>	129 (4.7%)	14 (12.2%)	0.0003
<b>Multifocality</b>	635 (23.1%)	27 (23.5%)	0.9248
<b>Mortality due to thyroid cancer</b>	150 (5.5%)	13 (11.3%)	0.0080
<b>Overall mortality</b>	252 (9.2%)	49 (42.6%)	0.0001

Anachronous, diagnosed 6 months before thyroid cancer diagnosis; synchronous, and metachronous, diagnosed 6 months after thyroid cancer diagnosis



**SUPPLEMENTAL FIGURE: Age distribution and case number of top three metachronous secondary primary malignancy.**